Two breakthrough GLP-1 medications, two slightly different mechanisms, and meaningfully different results. Here's how they compare — and how we help you choose.
Semaglutide and tirzepatide have rewritten what's possible with medical weight loss. Both are weekly injectables that work through the body's natural incretin system — the hormonal pathway that regulates appetite, blood sugar, and satiety after meals.
Semaglutide activates the GLP-1 receptor alone. Tirzepatide activates GLP-1 and GIP, a second incretin receptor, which appears to amplify weight loss and improve insulin sensitivity. The result: in head-to-head trials, tirzepatide consistently produces greater average weight loss — but semaglutide remains highly effective and is often the right starting point depending on your profile.
The medication is only part of the story. Lasting results come from pairing GLP-1 therapy with strength training, adequate protein, sleep, and hormone optimization — which is how we structure every weight loss plan at Sadhna.
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Wegovy, Ozempic | Mounjaro, Zepbound |
| Mechanism | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Avg. weight loss (72 wk, high dose) | ~15% body weight | ~20–22% body weight |
| Max weekly dose (weight loss) | 2.4 mg | 15 mg |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| A1C reduction (diabetic patients) | 1.5–1.8% | 1.9–2.4% |
| Common side effects | Nausea, constipation, fatigue | Nausea, diarrhea, fatigue |
| Titration time to full dose | 16–20 weeks | 20–24 weeks |
Data summarized from SURMOUNT-1, STEP-1, SUSTAIN, and SURPASS clinical trial programs.
Often the right starting point — well-studied, broadly available, and effective for most patients seeking 10–15% weight loss.
The newer dual-agonist with greater average weight loss in head-to-head data — often the right choice when goals exceed 15% body weight.
We evaluate your full metabolic panel, hormone status, insulin sensitivity, body composition, medication history, and goals before recommending either medication. For some patients we start with semaglutide and graduate to tirzepatide if results plateau. For others — particularly those with higher BMIs or metabolic syndrome — tirzepatide is the better first choice. Either way, the medication is paired with a full plan: nutrition, training, sleep, and hormone optimization to preserve muscle and protect long-term results.
We'll review your labs, goals, and medical history — then recommend the right protocol for your body.
